CLOV vs MOH

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

CLOV

33.4
AI Score
VS
MOH Wins

MOH

40.2
AI Score

Investment Advisor Scores

CLOV

33score
Recommendation
AVOID NEW MONEY

MOH

40score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric CLOV MOH Winner
Forward P/E 37.7358 21.3675 MOH
PEG Ratio 0 1.1367 Tie
Revenue Growth 53.1% -3.5% CLOV
Earnings Growth 0.0% -51.5% CLOV
Tradestie Score 33.4/100 40.2/100 MOH
Profit Margin 0.4% -0.1% CLOV
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD MOH

Relative Price Performance (Last 90 Days)

CLOV 1M: +3.3% · 3M: +10.7% MOH 1M: -0.1% · 3M: +1.7%

Current Technical Phase

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 60

RSI (14): 59.7 · Price: $4.97

MOH

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 52

RSI (14): 52.3 · Price: $209.25

Fundamentals Snapshot

Metric CLOV MOH
Market Cap — —
Forward P/E 27.6 21.9
Trailing P/E 493.0 —
Revenue (TTM) — —
Revenue Growth 0.5% 0.0%
Gross Margin 0.2% 0.1%
Operating Margin 0.0% 0.0%
EPS 0.01 -0.68
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MOH is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.